INS and diabetes mellitus: Glibenclamide therapy also prevented the diabetes-induced changes in insulin (Fig. 2g) and glucagon (Fig. 2h) staining, and in the area of individual islets, or whole pancreas, composed of ins+ and glu+ cells (Fig. 3a–d).